

# Corporate Action Notice

September 07, 2017

## Cash Distribution Resulting from the Sale of Rights

### PT Chandra Asri Petrochemical Tbk

DR CUSIP: 69368N209

DR ISIN: US69368N2099

DR TICKER SYMBOL: PTCAAY

Ratio (DRs: Underlying Shares): 1:50

BNY MELLON HAS ESTABLISHED THE  
FOLLOWING DATES FOR THIS  
CORPORATE ACTION:

DR Record Date: Sep 18, 2017

DR Payment Date: Sep 25, 2017

Foreign Exchange Rate: 13353

Gross Rate per DS: 0.798500

Depository Fee per DS: 0.050000

Net Rate per DS: 0.748500

PT Chandra Asri Petrochemical Tbk announced a distribution of rights to its Ordinary shareholders. The rights were allocated as follows: 4 right(s) were issued for every 47 Ordinary share(s) held as of the local record date of Aug 25, 2017.

PT Chandra Asri Petrochemical Tbk rights were not registered under the United States Securities Act of 1933, therefore we were not permitted to pass the rights on to the holders of Depositary Receipts ('DRs'). As a result, BNY Mellon has sold the rights in the local market and the proceeds received from the sale will be distributed to the DR holders of PT Chandra Asri Petrochemical Tbk.

---

To learn more about Depositary Receipts and issuer programs, please contact our marketing

#### NEW YORK

Ravi Davis  
Richard J Maehr  
+ 1 212 815 2267  
adrdesk@bnymellon.com

#### LONDON

Jacek Jankowski  
Vice President  
+ 44 207 163 7427  
jacek.jankowski@bnymellon.com

BNY Mellon is providing this information for general informational purposes only and does not warrant or guarantee the accuracy, timeliness or completeness of this information. BNY Mellon does not undertake any obligation to update or amend this information. BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. BNY Mellon collects fees from Depositary Receipt ("DR") holders pursuant to the terms and conditions of the DRs. BNY Mellon may make payments to sponsored DR issuers to reimburse and /or share revenue from the fees collected from DR holders, or waive fees and expenses for services provided. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates and in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at: [https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset\\_upload\\_file703\\_197380.pdf](https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset_upload_file703_197380.pdf). Depositary Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon, and are subject to investment risks.



BNY MELLON